Free Trial
NASDAQ:ATRC

AtriCure (ATRC) Stock Price, News & Analysis

AtriCure logo
$56.84 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$56.86 +0.02 (+0.04%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About AtriCure Stock (NASDAQ:ATRC)

Advanced

Key Stats

Today's Range
$55.81
▼
$57.28
50-Day Range
$51.52
▼
$65.53
52-Week Range
$25.36
▼
$66.02
Volume
558,769 shs
Average Volume
790,421 shs
Market Capitalization
$2.89 billion
P/E Ratio
189.47
Dividend Yield
N/A
Price Target
$62.30
Consensus Rating
Moderate Buy

Company Overview

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings.

The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation. AtriCure also offers products for managing post-operative pain.

Founded in 2000, AtriCure is headquartered in Mason, Ohio, and serves customers in the United States and international markets.

AI Generated. May Contain Errors.

AtriCure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

ATRC MarketRank™: 
2.676373262735 of 5 stars

AtriCure scored higher than 54% of companies evaluated by MarketBeat, and ranked 470th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for AtriCure is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    AtriCure has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about AtriCure's stock forecast and price target.
  • Earnings Growth

    Earnings for AtriCure are expected to grow by 13.64% in the coming year, from $0.44 to $0.50 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AtriCure is 189.47, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.16.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AtriCure is 189.47, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.45.

  • Price to Book Value per Share Ratio

    AtriCure has a P/B Ratio of 5.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.00% of the float of AtriCure has been sold short.
  • Short Interest Ratio / Days to Cover

    AtriCure has a short interest ratio ("days to cover") of 7.6.
  • Change versus previous month

    Short interest in AtriCure has recently increased by 0.07%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    AtriCure does not currently pay a dividend.

  • Dividend Growth

    AtriCure does not have a long track record of dividend growth.

  • News Sentiment

    AtriCure has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for AtriCure this week, compared to 4 articles on an average week.
  • Search Interest

    4 people have searched for ATRC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,172,263.00 in company stock.

  • Percentage Held by Insiders

    4.00% of the stock of AtriCure is held by insiders.

  • Percentage Held by Institutions

    99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AtriCure's insider trading history.
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATRC Stock News Headlines

AtriCure (NASDAQ:ATRC) Raised to Strong-Buy at Wall Street Zen
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
AtriCure (NASDAQ:ATRC) Sets New 12-Month High Following Earnings Beat
See More Headlines

ATRC Stock Analysis - Frequently Asked Questions

AtriCure's stock was trading at $39.56 at the start of the year. Since then, ATRC stock has increased by 43.7% and is now trading at $56.84.

AtriCure, Inc. (NASDAQ:ATRC) announced its earnings results on Tuesday, November, 3rd. The medical device company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.23. The medical device company had revenue of $154.45 million for the quarter, compared to the consensus estimate of $151.05 million. AtriCure had a net margin of 2.52% and a trailing twelve-month return on equity of 4.01%.
Read the conference call transcript
.

AtriCure subsidiaries include these companies: SentreHEART.

Top institutional investors of AtriCure include State Street Corp (4.18%), GW&K Investment Management LLC (1.78%), First Eagle Investment Management LLC (0.57%) and Public Sector Pension Investment Board (0.51%). Insiders that own company stock include Salvatore Privitera, Justin J Noznesky, Karl S Dahlquist, Vinayak Doraiswamy, Sven Wehrwein, Regina E Groves, Karen Prange and Maggie Yuen.
View institutional ownership trends
.

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Chevron (CVX), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Verizon Communications (VZ), C3.ai (AI), CVS Health (CVS) and Delta Air Lines (DAL).

Company Calendar

Last Earnings
11/03/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:ATRC
CIK
1323885
Employees
1,350
Year Founded
2000

Price Target and Rating

High Price Target
$70.00
Low Price Target
$44.00
Potential Upside/Downside
+9.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.58
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.30
Trailing P/E Ratio
189.47
Forward P/E Ratio
113.68
P/E Growth
N/A
Net Income
-$11.45 million
Net Margins
2.52%
Pretax Margin
2.75%
Return on Equity
4.01%
Return on Assets
3.03%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
4.33
Quick Ratio
3.29

Sales & Book Value

Annual Sales
$534.53 million
Price / Sales
5.41
Cash Flow
$0.31 per share
Price / Cash Flow
181.60
Book Value
$9.89 per share
Price / Book
5.75

Miscellaneous

Outstanding Shares
50,920,000
Free Float
48,885,000
Market Cap
$2.89 billion
Optionable
Optionable
Beta
1.22

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:ATRC) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners